JP3770515B2 - Oral concealment agent for drug bitterness - Google Patents

Oral concealment agent for drug bitterness Download PDF

Info

Publication number
JP3770515B2
JP3770515B2 JP28426897A JP28426897A JP3770515B2 JP 3770515 B2 JP3770515 B2 JP 3770515B2 JP 28426897 A JP28426897 A JP 28426897A JP 28426897 A JP28426897 A JP 28426897A JP 3770515 B2 JP3770515 B2 JP 3770515B2
Authority
JP
Japan
Prior art keywords
drug
oral
unpleasant taste
hydrochloride
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP28426897A
Other languages
Japanese (ja)
Other versions
JPH11106354A (en
Inventor
努 原田
宏治 鵜飼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Priority to JP28426897A priority Critical patent/JP3770515B2/en
Publication of JPH11106354A publication Critical patent/JPH11106354A/en
Application granted granted Critical
Publication of JP3770515B2 publication Critical patent/JP3770515B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Description

【0001】
【産業上の利用分野】
本発明は、薬物の不快な味を隠蔽した経口剤に関する。
【0002】
【発明の背景及び従来技術】
投与剤の剤形の一つとしてシロップ等の経口液剤が知られており、小児、老人等に適した剤形として広く使用されている。シロップ剤は、甘味を有する剤形であるが、溶解する薬物が不快な味を有していると、単に甘味だけでは隠蔽できず服用し難く、コンプライアンスも低下する。
【0003】
一方、不快な味を有する薬物のマスキングには多くの技術が開発されている。例えば、顆粒剤を水溶性の皮膜によりコーティングする方法、融点40℃〜100℃のワックス類を溶融し、その中に不快な風味を呈する薬物を分散後、固化させて散剤などを得る方法等が知られている。
【0004】
【発明が解決しようとする課題】
不快な味を有する薬物のマスキングを目的として前述のような多くの技術が検討されているが、多くは固形薬剤に関するものであり、経口用液剤に適用できるものは知られていない。
【0005】
【課題を解決するための手段】
本発明は、不快な味を有する薬物に無水ケイ酸を配合して成る、不快な味を隠蔽した経口剤である。
【0006】
本発明における、不快な味を有する薬物としては、例えば、塩酸ドネペジル、塩酸ビフェメラン、塩酸ホモクロルシクリジン、塩酸ブナゾシン又はビタミンB1 、B2 、B6 、パントテン酸カルシウム、ニコチン酸アミド、或いはそれらの誘導体、並びに塩酸チクロピジン、塩化ベルベリン、ジギトキシン、スルピリン、塩酸アゼラスチン、塩酸エチレフリン、塩酸ジルチアゼム、塩酸プロプラノロール、クロラムフェニコール、アミノフィリン、エリスロマイシン、フェノバルビタール、パントテン酸カルシウム、塩酸インデロキサジン、塩酸アミノグアニジンなどを挙げることができる。これらのうち、特に、塩酸ドネペジルの場合に優れた効果を奏する。塩酸ドネペジルは、次の構造式
【0007】
【化1】

Figure 0003770515
【0008】
によって表される1−ベンジル−4−(5,6−ジメトキシインダノン−2−イル)メチルピペリジン塩酸塩である。このものは、軽度から中等度のアルツハイマー治療剤であるが、その水溶液は激しい苦味、口腔内のしびれがある。
【0009】
本発明者等は鋭意検討の結果、意外にも、不快な味を有する薬物に無水ケイ酸を配合することにより、不快な味が顕著に隠蔽されることを見出し、本発明を完成した。すなわち、本発明においては、隠蔽剤として無水ケイ酸を使用するものである。
【0010】
無水ケイ酸の製法には、気相法と液相法とが知られている。気相法による製剤(気相製)は特に軽質無水ケイ酸と称されている。代表的にはアエロジル(Aerosil)が、市場で入手可能である。これら軽質無水ケイ酸は従来、例えば、軟膏などの増粘剤、乳化液の安定剤として使用されている。しかしながら、経口用液剤として不快な味を有する薬物に配合した場合に、その不快な味を隠蔽する作用、効果があることについての記載は皆無である。
【0011】
本発明における経口剤とは、溶液又はゼリーとして経口的に服用される剤形を意味し、溶液の具体例としてはシロップ剤、エリキシル剤、乳剤等を挙げることができるが、シロップ剤が特に好ましい。
【0012】
シロップ剤とは、白糖の溶液又は白糖、その他の糖類若しくは甘味剤を含む医薬品を比較的濃稠な溶液又は懸濁液などとした液状の内用剤であり、通常、白糖やその他の甘味剤の溶液又は単シロップに医薬品を加えて溶解、混和、懸濁又は乳化し、必要に応じて混液を煮沸した後、熱時濾過して製造する。
【0013】
エリキシル剤とは、通常、甘味及び芳香のあるエタノールを含む澄明な液状の内用剤であり、通常、医薬品にエタノール、精製水、芳香剤及び白糖、その他の糖類又は甘味剤を加えて溶かし、濾過又はその他の方法によって澄明な液を製する。
【0014】
ゼリー剤とは、あらゆる溶媒に不溶の三次元網目構造をもつ高分子およびその膨潤体(高分子学会編新版高分子辞典)であり、多量の溶媒を吸収した膨潤ゲルは固体と液体の中間の物質形態であり、その組成や種々の要因によって粘性のある液体からかなり固い固体にまで変化する。ゼリーには寒天ゼリー、ゼラチンゼリー、ペクチンゼリー等がある。
【0015】
本発明に係る経口用者への投与方法は特に限定されず、薬物の性質により、食前、食後又は食間に1日当り1から3回経口的に投与することができる。
【0016】
本発明における、薬剤と、無水ケイ酸(隠蔽剤)の割合は、一般に、薬剤1重量部に対し、隠蔽剤25から70重量部であり、好ましくは40から70重量部である。
【0017】
不快な味を隠蔽した経口液剤中の薬剤の濃度は、一般に0.2から50mg/ml である。例えば、塩酸ドネペジルの場合は、その濃度は1〜2mg/ml 又はゼリー剤の場合は1〜2mg/gが好ましい。
【0018】
また本発明に係る不快な味を隠蔽した経口液剤の製造方法は、特に限定されず、薬剤及び隠蔽剤を水に溶解して製造することができる。更に、ショ糖、マンニトール、グルコース、アスパルテーム、ソルビトール、グリシン、サッカリン等の甘味剤、バニラエッセンス、ストロベリーエッセンス、オレンジエッセンス、グレープエッセンス、アップルフレーバー等の矯味剤等を加えることもできる。
【0019】
【発明の効果】
本発明に係る経口液剤は、薬剤特有の苦味、しびれ、収斂性等の不快な味が隠蔽されているため、非常に服用し易く、特に幼児、老齢者のコンプライアンスが向上する。本発明に係る経口液剤が、不快な味を隠蔽するメカニズムは次のように考えられる。即ち、水溶液中の不快な味を有する薬物が、隠蔽剤と相互作用を起こし、溶液中の遊離体が減少することにより、舌の苦味レセプターへの結合率を減少させると共に、しびれの発現も低減させるものと考えられる。
【0020】
試験例1
1mg/ml の塩酸ドネペジル水溶液を調整し、その10mlにアエロジル400mgを溶解後、2名の被験者が全量を口に含み、苦味と、しびれの程度を5段階で評価した。結果を表1に示した。表1により明らかなように、隠蔽剤の添加によって塩酸ドネペジルの苦味は顕著に抑制された。
【0021】
【表1】
Figure 0003770515
【0022】
【実施例】
以下に実施例を挙げて本発明を更に詳細に説明する。ただし、本発明はこれらの実施例に限定されるものではない。
【0023】
実施例1
塩酸ドネペジル1gを精製水約100gに溶解した。別途、アエロジル40g、クエン酸ナトリウム5gおよびアスパルテーム(パルスイートダイエット)3gを精製水300gに溶解した。次いで、両溶液を均一になるまで混合した。さらにメチルパラベン1g及びプロピルパラベン0.1gをプロピレングリコール10gに溶解し、これを主薬溶液にゆっくり添加した。赤色40号3mgおよびストロベリーエッセンス0.5gを加えた後、クエン酸を用いpH5に調整し、最後に総重量500gになるように精製水で調整したペースト状のシロップを製造した。
【0024】
実施例2
塩酸ドネペジル1gを精製水約50gに溶解した。別途、アエロジル12.5g、アルギン酸ナトリウム15g、クエン酸ナトリウム5gおよびソルビトール125gを精製水250gに溶解した。次いで、両溶液を均一になるまで混合した。さらにメチルパラベン1g及びプロピルパラベン0.1gをプロピレングリコール10gに溶解し、これを主薬溶液にゆっくり添加した。赤色40号3mgおよびストロベリーエッセンス0.5gを加えた後、クエン酸を用いpH5に調整し、最後に総重量500gになるように精製水で調整し、ゼリー剤を製造した。[0001]
[Industrial application fields]
The present invention relates to an oral preparation that masks an unpleasant taste of a drug.
[0002]
BACKGROUND OF THE INVENTION AND PRIOR ART
Oral liquids such as syrup are known as one of dosage forms for administration, and are widely used as dosage forms suitable for children, the elderly and the like. A syrup is a sweet dosage form, but if the drug to be dissolved has an unpleasant taste, it cannot be concealed simply by sweetness and is difficult to take, and compliance is also reduced.
[0003]
On the other hand, many techniques have been developed for masking drugs having an unpleasant taste. For example, a method of coating a granule with a water-soluble film, a method of melting a wax having a melting point of 40 ° C. to 100 ° C., dispersing a drug exhibiting an unpleasant flavor therein, and solidifying it to obtain a powder or the like Are known.
[0004]
[Problems to be solved by the invention]
Many techniques as described above have been studied for the purpose of masking drugs having an unpleasant taste, but many are related to solid drugs, and those applicable to oral liquids are not known.
[0005]
[Means for Solving the Problems]
The present invention is an oral preparation that conceals an unpleasant taste, comprising an unpleasant taste drug mixed with silicic anhydride.
[0006]
Examples of the drug having an unpleasant taste in the present invention include donepezil hydrochloride, bifemelane hydrochloride, homochlorcyclidine hydrochloride, bunazosin hydrochloride or vitamin B 1 , B 2 , B 6 , calcium pantothenate, nicotinamide, or the like And ticlopidine hydrochloride, berberine chloride, digitoxin, sulpyrine, azelastine hydrochloride, ethylephrine hydrochloride, diltiazem hydrochloride, propranolol hydrochloride, chloramphenicol, aminophylline, erythromycin, phenobarbital, calcium pantothenate, indeloxazine hydrochloride, aminoguanidine hydrochloride And so on. Of these, particularly excellent effect is obtained in the case of donepezil hydrochloride. Donepezil hydrochloride has the following structural formula:
[Chemical 1]
Figure 0003770515
[0008]
1-benzyl-4- (5,6-dimethoxyindanon-2-yl) methylpiperidine hydrochloride represented by This is a mild to moderate Alzheimer's treatment, but its aqueous solution has severe bitterness and numbness in the oral cavity.
[0009]
As a result of intensive studies, the present inventors have surprisingly found that an unpleasant taste is concealed conspicuously by adding silicic anhydride to a drug having an unpleasant taste, and the present invention has been completed. That is, in the present invention, silicic anhydride is used as a masking agent.
[0010]
As a method for producing silicic anhydride, a gas phase method and a liquid phase method are known. The preparation by gas phase method (made by gas phase) is particularly called light anhydrous silicic acid. Typically, Aerosil is available on the market. These light silicic anhydrides are conventionally used as thickeners such as ointments and stabilizers for emulsions. However, there is no description about the action and effect of concealing the unpleasant taste when blended with a drug having an unpleasant taste as an oral liquid.
[0011]
The oral preparation in the present invention means a dosage form to be taken orally as a solution or jelly, and specific examples of the solution can include syrups, elixirs, emulsions and the like, with syrups being particularly preferred. .
[0012]
A syrup is a liquid internal preparation in which a sucrose solution or a pharmaceutical containing sucrose, other saccharides, or a sweetener is used as a relatively concentrated solution or suspension. Usually, sucrose or other sweeteners are used. A pharmaceutical product is added to a solution or a simple syrup to dissolve, mix, suspend or emulsify, and if necessary, the mixture is boiled and then filtered while hot.
[0013]
An elixir is usually a clear liquid internal preparation containing ethanol with sweetness and fragrance, and usually dissolved in ethanol by adding ethanol, purified water, fragrance and sucrose, other saccharides or sweeteners, A clear liquid is produced by filtration or other methods.
[0014]
A jelly agent is a polymer having a three-dimensional network structure that is insoluble in any solvent and its swelled material (a new edition of the polymer dictionary edited by the Society of Polymer Science). It is a substance form and changes from a viscous liquid to a fairly hard solid depending on its composition and various factors. The jelly includes agar jelly, gelatin jelly, pectin jelly and the like.
[0015]
The administration method to the oral user according to the present invention is not particularly limited, and can be orally administered 1 to 3 times per day before, after, or between meals depending on the nature of the drug.
[0016]
In the present invention, the ratio of the drug and silicic acid anhydride (masking agent) is generally 25 to 70 parts by weight, preferably 40 to 70 parts by weight with respect to 1 part by weight of the drug.
[0017]
The concentration of drug in oral solutions that mask the unpleasant taste is generally 0.2 to 50 mg / ml. For example, in the case of donepezil hydrochloride, the concentration is preferably 1 to 2 mg / ml, or 1 to 2 mg / g in the case of a jelly agent.
[0018]
Moreover, the manufacturing method of the oral liquid agent which masked the unpleasant taste which concerns on this invention is not specifically limited, It can manufacture by melt | dissolving a chemical | medical agent and a masking agent in water. Furthermore, sweeteners such as sucrose, mannitol, glucose, aspartame, sorbitol, glycine, and saccharin, and flavoring agents such as vanilla essence, strawberry essence, orange essence, grape essence, and apple flavor can be added.
[0019]
【The invention's effect】
The oral solution according to the present invention hides unpleasant tastes such as the bitterness, numbness, and astringency peculiar to the drug, so it is very easy to take and improves the compliance of infants and the elderly in particular. The mechanism by which the oral solution according to the present invention masks an unpleasant taste is considered as follows. That is, drugs with an unpleasant taste in aqueous solution interact with the masking agent, reducing the free substance in the solution, thereby reducing the binding rate of the tongue to the bitter taste receptor and reducing the occurrence of numbness. It is thought that
[0020]
Test example 1
A 1 mg / ml donepezil hydrochloride aqueous solution was prepared, and 400 mg of Aerosil was dissolved in 10 ml of the solution, and then two subjects included the entire amount in their mouths, and the bitterness and numbness were evaluated in five stages. The results are shown in Table 1. As is clear from Table 1, the bitter taste of donepezil hydrochloride was significantly suppressed by the addition of the masking agent.
[0021]
[Table 1]
Figure 0003770515
[0022]
【Example】
Hereinafter, the present invention will be described in more detail with reference to examples. However, the present invention is not limited to these examples.
[0023]
Example 1
1 g of donepezil hydrochloride was dissolved in about 100 g of purified water. Separately, 40 g of Aerosil, 5 g of sodium citrate and 3 g of aspartame (Pal sweet diet) were dissolved in 300 g of purified water. Both solutions were then mixed until uniform. Further, 1 g of methylparaben and 0.1 g of propylparaben were dissolved in 10 g of propylene glycol, and this was slowly added to the main agent solution. After adding 3 mg of red No. 40 and 0.5 g of strawberry essence, pH was adjusted to 5 using citric acid, and finally a paste-like syrup was prepared which was adjusted with purified water to a total weight of 500 g.
[0024]
Example 2
1 g of donepezil hydrochloride was dissolved in about 50 g of purified water. Separately, 12.5 g of Aerosil, 15 g of sodium alginate, 5 g of sodium citrate and 125 g of sorbitol were dissolved in 250 g of purified water. Both solutions were then mixed until uniform. Further, 1 g of methylparaben and 0.1 g of propylparaben were dissolved in 10 g of propylene glycol, and this was slowly added to the main agent solution. After adding 3 mg of red No. 40 and 0.5 g of strawberry essence, it was adjusted to pH 5 using citric acid, and finally adjusted with purified water to a total weight of 500 g to produce a jelly preparation.

Claims (2)

不快な味を有する薬物、および薬物1重量部に対して25〜70重量部の無水ケイ酸を配合した液剤、ペ−スト剤、ゼリー剤、シロップ剤、エリキシル剤または乳剤である経口剤。An oral preparation which is a liquid, paste, jelly, syrup, elixir or emulsion containing a drug having an unpleasant taste and 25 to 70 parts by weight of silicic acid based on 1 part by weight of the drug. 不快な味を有する薬物に、薬物1重量部に対して25〜70重量部の無水ケイ酸を配合し、液剤、ペ−スト剤、ゼリー剤、シロップ剤、エリキシル剤または乳剤とする薬物の不快味の隠蔽方法。Drug unpleasant taste that contains 25-70 parts by weight of silicic acid to 1 part by weight of the drug to form a solution, paste, jelly, syrup, elixir or emulsion Taste concealment method.
JP28426897A 1997-10-02 1997-10-02 Oral concealment agent for drug bitterness Expired - Lifetime JP3770515B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP28426897A JP3770515B2 (en) 1997-10-02 1997-10-02 Oral concealment agent for drug bitterness

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP28426897A JP3770515B2 (en) 1997-10-02 1997-10-02 Oral concealment agent for drug bitterness

Publications (2)

Publication Number Publication Date
JPH11106354A JPH11106354A (en) 1999-04-20
JP3770515B2 true JP3770515B2 (en) 2006-04-26

Family

ID=17676336

Family Applications (1)

Application Number Title Priority Date Filing Date
JP28426897A Expired - Lifetime JP3770515B2 (en) 1997-10-02 1997-10-02 Oral concealment agent for drug bitterness

Country Status (1)

Country Link
JP (1) JP3770515B2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001342151A (en) * 2000-03-31 2001-12-11 Eisai Co Ltd Pharmaceutical composition having sweet taste
CA2552221A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
LT2486942T (en) 2004-11-24 2019-01-25 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
JP5491943B2 (en) * 2010-04-28 2014-05-14 ゼリア新薬工業株式会社 Oral jelly containing vitamin B1
CN110507610A (en) * 2019-07-24 2019-11-29 西北农林科技大学 A kind of nanoemulsion medicine and preparation method thereof containing vitamin D

Also Published As

Publication number Publication date
JPH11106354A (en) 1999-04-20

Similar Documents

Publication Publication Date Title
JP5053228B2 (en) Oral drugs concealing bitterness
AU635283B2 (en) Aqeous pharmaceutical suspension for substantially water insoluble pharmaceutical actives
JP3778518B2 (en) Aqueous liquid composition with good taste for bitter drugs
JPH09508402A (en) Oral liquid composition containing paroxetine-resin
JP4051717B2 (en) Biotin-containing oral solution
CN109893502B (en) Tofacitinib citrate composition and preparation method thereof
JP3770515B2 (en) Oral concealment agent for drug bitterness
JP3770518B2 (en) Oral drugs concealing bitterness
JP4190769B2 (en) Oral liquid composition
JPH04327526A (en) Solid pharmaceutical for oral use
JPH0543474A (en) Herb preparation composition for ready administration
JP2001031562A (en) Liquid preparation for internal use
JPS63156719A (en) Syrup
JP4234666B2 (en) Oral drugs concealing bitterness
JP4990515B2 (en) Isosorbide preparation with improved taste quality
WO2005072717A1 (en) Biguanide preparation for internal use
JP2000119198A (en) Phosphodiesterase inhibitor-containing peroral preparation hiding bitterness or the like
JP3666094B2 (en) Calcium liquid, calcium beverage and method for producing the same
AU4782600A (en) Oral preparations of etidronate disodium
JP4959864B2 (en) Glutamate-containing solution
JPH05255092A (en) Composition for intestinal canal lavage
JP3294033B2 (en) Oblate
JP2001342151A (en) Pharmaceutical composition having sweet taste
JPH10265369A (en) Liquid agent for internal use having improved taste
JPH1036252A (en) Oral liquid medicine combined with belladonna (total) alkaloid

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20040914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040916

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20060202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20060203

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100217

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100217

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20180217

Year of fee payment: 12

EXPY Cancellation because of completion of term